Search Results for "Neupro"

16:27 EDT 2nd August 2015 | BioPortfolio

Matching Channels


Matching News

BRIEF-UCB advances Neupro in China

* Announced positive top-line results from two phase 3 studies evaluating Neupro in treatment of patients in China

UCB's Neupro meets in Chinese Phase III PD trial

UCB Group (Euronext:UCB) reported detailed data from a Phase III trial of Neupro rotigotine in Chinese patients with early stage Parkinson's disease (PD). The company announced top-line results in Feb...

UCB Patch Product for Parkinson's Passes China Phase III Test

UCB, the Belgian biopharma, reported positive results from a China Phase III trial of its transdermal patch product, NEUPRO®, a treatment for early stage Parkinson's disease. NEUPRO (rotigotine) i...

UCB’s Phase III results for Neupro will back filing in China this year

Belgian drugmaker UCB has announced positive top-line results from two Phase III studies of Neupro (rotigotine transdermal patch) in patients in China with early- and advanced-stage idiopathic Parkins...

BRIEF-UCB announces data from Neupro phase 3 study

* Announces first presentation of data from Neupro (rotigotine transdermal patch) phase 3 study in China at international congress

UCB to File for China Approval of Parkinson's Disease Patch

UCB of Belgium reported positive results from two China Phase III trials of Neupro, a dopamine agonist patch product, for early and advanced-stage Parkinson's disease. The company said it would comple...

Neupro rotigotine: Phase III data

UCB Full Year Report 2014: Core medicines grow by 24% while next wave of new potential solutions for patients advances

"UCB continues its growth path with Cimzia®, Vimpat® and Neupro®, now accounting for 50% of our net sales. We continue to advance and prepare the launches of our next wave of potential new patient ...

Matching PubMed Articles


Search Whole site using Google


Advertisement Advertisement